Englander Institute for Precision Medicine

A team of Weill Cornell Medicine investigators is working to cross-train the next generation of cancer researchers in cancer biology and the use of artificial intelligence tools for research.

We sat down with Dr. Jia Ruan to learn more about her clinical research and how she thinks it will help lymphoma patients.

A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.

Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation. 

More than 100 students from across Cornell campuses and 17 other universities gathered in New York City March 6–8 for the Cornell Health AI Hackathon.

An enigmatic type of circulating tumor cell called a dual-positive cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine. 

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. 

Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to work with researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center on an AI-based method for early detection of treatment-resistant prostate tumor subtypes.

Dr. George Coukos, an internationally renowned expert on cancer immunology, is launching the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine.

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Dr. Ekta Khurana highlights the goals of a recently paused Department of Defense grant investigating treatment-resistant prostate cancer—and the consequences of further inaction.

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in individual cancer cells.

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest to treat breast cancers, but a new study led by Weill Cornell Medicine suggests a way to stop it from spreading.

Scientists have discovered a method to induce human endothelial cells from a small biopsy sample to multiply in the laboratory, producing more than enough cells to replace damaged blood vessels or nourish organs for transplantation, according to a preclinical study by Weill Cornell Medicine investigators.

Weill Cornell Medicine researchers have discovered that PD-1—a molecule best known for putting the brakes on immune cells—also plays a critical role in helping T cells become long-term immune defenders in the skin.

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. 

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

The way DNA folds inside the nucleus of brain cells may hold the key to understanding a devastating form of brain cancer called glioblastoma, suggests a new preclinical study from Weill Cornell Medicine researchers.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators.